Skip to main content

Table 4 Odds of systemic adverse events within 1 week after MenACWY vaccination adjusted for the odds before vaccination

From: Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study

 

OR (95% CI)a

Fatigue

0.34 (0.18–0.65)

Sleeping problems

0.22 (0.07–0.67)

Irritable

0.29 (0.12–0.71)

Fever

1.01 (0.22–4.71)

Cough

0.51 (0.22–1.17)

Common cold

0.50 (0.27–0.91)

Listless/apathetic

0.24 (0.10–0.55)

Dyspnea

0.81 (0.25–2.65)

Headache

0.70 (0.38–1.29)

Decreased appetite

0.55 (0.21–1.45)

Vomiting

0.20 (0.02–1.77)

Diarrhea

0.57 (0.19–1.73)

Lower abdominal pain

0.57 (0.26–1.25)

Nausea

0.66 (0.27–1.66)

Dizziness

0.73 (0.31–1.71)

Fainting

Did not converge

Myalgia

1.04 (0.60–1.78)

Joint pain

0.44 (0.15–1.27)

Muscular spasm

1.75 (0.61–5.01)

Sweating

Did not converge

Rash

0.39 (0.16–0.99)

Itch

0.43 (0.17–1.07)

Other

0.81 (0.25–2.61)

All systemic events

0.43 (0.23–0.81)

  1. aGLMM analysis; adjusted for sex